Zilebesiran in Hypertension: Reversibility, Acute Illness, and Therapeutic Flexibility.

Endothelin receptor antagonism for resistant hypertension in chronic kidney disease: where does aprocitentan fit?

Resistant hypertension, defined as blood pressure (BP) above target despite maximally tolerated doses of at least three antihypertensive agents, including a diuretic, after excluding pseudo-resistance, is common in chronic kidney disease (CKD), and is associated with persistently low rates of BP control [ 1 , 2 ]. Unco...

Efficacy and safety of zilebesiran in adults with hypertension: a systematic review and meta-analysis of randomized controlled trials

Overall, zilebesiran produced significant and consistent BP reductions, especially in ambulatory measures, with a favorable safety profile, and builds on previous meta-analyses that included only 2 RCTs; this updated analysis reflects the need for novel therapeutic options.

Tolvaptan in heart failure: Contemporary evidence and a framework for precision decongestion

Renal Denervation for Hypertension Management: Past, Current Evidence and Future Directions.

Hypertension remains the most prevalent modifiable cardiovascular risk factor worldwide, and continues to account for substantial morbidity, mortality, and health care burden despite established pharmacologic and lifestyle-based therapies. Poor long-term adherence, therapeutic inertia, polypharmacy, and persistent impl...

Hopes and doubts about zilebesiran, a new antihypertensive drug.

The aim of this work is to critically evaluate the benefits and risks of zilebesiran. A comprehensive literature search was conducted in PubMed and Google Scholar databases to identify relevant studies on zilebesiran and other small-interfering RNA (siRNA)-based therapies for hypertension. The search covered publicatio...

A comparative analysis on safety and efficacy of telmisartan and ramipril in treatment of hypertension in a tertiary care hospital

Background: Hypertension is a major global health challenge and an important risk factor for cardiovascular disease. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly used first-line antihypertensive agents. This study evaluated the safety and efficacy of telmisartan...